( PhaseI/II trial 22 patients (65%) exp...)Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting,Health

Phase I/II trial, 22 patients (65%) experienced a confirmed decline in prostate specific antigen (PSA) levels of greater than 50%, with 10 of the 34 patients (29%) experiencing PSA declines of greater than 90%. Of the 20 evaluable patients with measurable tumor lesions, treatment with CB7630 resulted in partial radiological responses (as measured by the RECIST criteria) in 11 patients (55%), with 7 patients demonstrating ongoing stable disease and 3 patients experienced regressing bone disease. Several patients treated with CB7630 also experienced improvement in pain and a notable reduction in opioid use. Circulating tumor cells (CTC) were detected in 16 of 34 patients and changes in CTC counts were shown to correlate with changes in PSA.

Currently 30 of the 42 evaluable patients (71%) in the Phase I/II trial remain on study and continue to be treated with CB7630. Of the 15 patients in the Phase I stage of the trial, 9 patients (60%) are still receiving treatment with CB7630 with the average patient having received the drug for over 9.7 months, including 5 patients having received the drug for over 12 months. Of the 12 patients who started the trial longer than 9 months ago, 8 patients (67%) have shown a confirmed response that has lasted longer than 9 months and these responses continue in all but one of these patients.

In his poster, Dr Attard also provided an update on the Phase II trial of CB7630 in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy. The Phase II trial is being conducted at numerous locations in the United States and United Kingdom. In the trial, CB7630 is administered orally, once daily, to patients with castration refractory prostate cancer who have failed treatment with first line docetaxel based chemotherapy.

To date, 38 patients have been treated in this Phase II trial with 13 of the patients having been treated for over 3 months. Of the 38 patients who have been
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis